Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V920 (Ervebo) Consistency and High Dose Lots in Healthy Adults
NCT02503202Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- Viral Vector Vaccines
01
Overview
A Phase 3 trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD), sponsored by Merck & Co.. Started Aug 2015; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02503202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503202.